Skip to content

Study · Systematic review · n = 1,541 · 2024

4 results

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.

Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C

Expert opinion on pharmacotherapy18 Apr 2024Cited by 76 (Europe PMC)

PMID38629387 (opens in a new tab)DOI10.1080/14656566.2024.2343092 (opens in a new tab)PepBankPUB-38629387
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In overweight or obese adults, semaglutide produced significant weight reductions that were primarily due to fat mass loss.

    In plain wordsIn overweight or obese adults, weight loss on semaglutide came mainly from fat mass in the reviewed studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction by fat mass loss
    Study

    n = 1,541

    Comparator
    Placebo or alternative medications
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Six studies with 1,541 overweight or obese adults were included, and significant weight reductions were observed primarily due to fat mass loss.
    2 context sentences
    Summary · context
    This study investigates through different databases (PubMed, Elsevier, and Google Scholar) from 2016 for randomized control trials (RCTs) or observational studies that assessed the use of semaglutide in overweight or obese patients, regardless of whether they have type 2 diabetes or not.
    Summary · context
    The studies compared semaglutide to a placebo or alternative medications.
  2. 02HumanSystematic reviewEfficacy outcome

    In overweight or obese adults on semaglutide, lean mass stayed stable in some studies, with reductions of almost 0% to 40% of total weight reduction in others.

    In plain wordsIn overweight or obese adults, lean mass stayed stable in some studies but made up almost 0% to 40% of weight lost in others.

    Peptide
    Semaglutide
    Outcome
    MixedLean mass loss as share of weight reduction
    Study

    n = 1,541

    Comparator
    Placebo or alternative medications
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others.
    2 context sentences
    Summary · context
    This study investigates through different databases (PubMed, Elsevier, and Google Scholar) from 2016 for randomized control trials (RCTs) or observational studies that assessed the use of semaglutide in overweight or obese patients, regardless of whether they have type 2 diabetes or not.
    Summary · context
    The studies compared semaglutide to a placebo or alternative medications.
  3. 03HumanSystematic reviewEfficacy outcome

    In overweight or obese adults, noteworthy decreases in lean mass on semaglutide were particularly evident in larger trials.

    In plain wordsIn overweight or obese adults, larger trials showed clear drops in lean mass with semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseLean mass decrease in larger trials
    Study

    n = 1,541

    Comparator
    Placebo or alternative medications
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Noteworthy decreases in lean mass were particularly evident in larger trials
    2 context sentences
    Summary · context
    This study investigates through different databases (PubMed, Elsevier, and Google Scholar) from 2016 for randomized control trials (RCTs) or observational studies that assessed the use of semaglutide in overweight or obese patients, regardless of whether they have type 2 diabetes or not.
    Summary · context
    The studies compared semaglutide to a placebo or alternative medications.
  4. 04HumanSystematic reviewEfficacy outcome

    In overweight or obese adults on semaglutide, the proportion of lean mass relative to total body mass increased.

    In plain wordsIn overweight or obese adults, lean mass made up a larger share of total body mass after semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseLean mass proportion of total body mass
    Study

    n = 1,541

    Comparator
    Placebo or alternative medications
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    yet the proportion of lean mass relative to total body mass increased, suggesting a positive overall outcome.
    2 context sentences
    Summary · context
    This study investigates through different databases (PubMed, Elsevier, and Google Scholar) from 2016 for randomized control trials (RCTs) or observational studies that assessed the use of semaglutide in overweight or obese patients, regardless of whether they have type 2 diabetes or not.
    Summary · context
    The studies compared semaglutide to a placebo or alternative medications.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07702461

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Ohio State Universityn = 30012 Jun 2026 to est. Jan 2027

Obesity & Overweight · Diabetes (DM)

Trial pageClinicalTrials.govUpdated 24 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.